A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2
Authors:
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Environment International
- Vol. 147, 106361
Abstract
No abstract availableKeywords
Funding Information
- Academy of Military Medical Sciences
- Academy of Military Medical Sciences
This publication has 34 references indexed in Scilit:
- Importation and Human-to-Human Transmission of a Novel Coronavirus in VietnamNew England Journal of Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2PLOS Pathogens, 2018
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmationBioorganic & Medicinal Chemistry Letters, 2011
- Core Structure of S2 from the Human Coronavirus NL63 Spike Glycoprotein,Biochemistry, 2006
- Insights from the Association of SARS-CoV S-Protein with its Receptor, ACE22006
- Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2The EMBO Journal, 2005
- A model of the ACE2 structure and function as a SARS-CoV receptorBiochemical and Biophysical Research Communications, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003